Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety.

Ying Liu(Zhengzhou University), Danyang Li(Zhengzhou University), Qingxin Xia(Zhengzhou University), Chengjuan Zhang(Zhengzhou University), Baodong Li(Zhengzhou University), Hongle Li(Zhengzhou University), Jinbang Wang(Dalian National Laboratory for Clean Energy), Guangsen Han(Zhengzhou University), Gangcheng Wang(Zhengzhou University), Jing Zhuang(Zhengzhou University), Zhi Li(First Affiliated Hospital of Wannan Medical College), Ke Li(Xi'an University of Science and Technology), Lei Qiao(State Key Laboratory for Innovation and Transformation of Luobing Theory), Juan Yu(Southern Medical University), Zhimeng Li(Zhengzhou University), Shuning Xu(Zhengzhou University), Yuzhou Zhao(Zhengzhou University), Gaizhen Kuang(Zhengzhou University)
Journal of Clinical Oncology
May 20, 2021
Cited by 36


Related Papers